BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report report published on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Price Performance

Shares of NASDAQ BLRX opened at $0.46 on Friday. BioLineRx has a fifty-two week low of $0.39 and a fifty-two week high of $1.89. The company has a market cap of $37.00 million, a PE ratio of -1.03 and a beta of 1.48. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The business has a 50-day simple moving average of $0.51 and a two-hundred day simple moving average of $0.62.

Hedge Funds Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLRX. PVG Asset Management Corp acquired a new position in shares of BioLineRx in the second quarter valued at about $70,000. Atria Investments Inc boosted its position in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC acquired a new position in BioLineRx in the 2nd quarter worth approximately $462,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.